A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

• Status: RECRUITING
• Trial end date: 2028-05-08

Summary

This study will evaluate the pharmacokinetics (PK), safety, and efficacy of cevostamab in participants with relapsed or refractory (R/R) multiple myeloma (MM).

• Phase: PHASE1

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: tocilizumab